Exact Sciences Corp (EXAS) Reports In-Line Q3 EPS Loss of $0.15
Exact Sciences Corp (NASDAQ: EXAS) reported Q3 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.03 million.